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Abstract: Cardiovascular disease (CVD) risk shows a clear sexual dimorphism with age, with a
lower incidence in young women compared to age-matched men. However, this protection is lost
after menopause. We demonstrate that sex-biased sensitivity to the development of CVD with age
runs in parallel with changes in G protein-coupled receptor kinase 2 (GRK2) protein levels in the
murine heart and that mitochondrial fusion markers, related to mitochondrial functionality and
cardiac health, inversely correlate with GRK2. Young female mice display lower amounts of cardiac
GRK2 protein compared to age-matched males, whereas GRK2 is upregulated with age specifically
in female hearts. Such an increase in GRK2 seems to be specific to the cardiac muscle since a different
pattern is found in the skeletal muscles of aging females. Changes in the cardiac GRK2 protein do
not seem to rely on transcriptional modulation since adrbk1 mRNA does not change with age and
no differences are found between sexes. Global changes in proteasomal or autophagic machinery
(known regulators of GRK2 dosage) do not seem to correlate with the observed GRK2 dynamics.
Interestingly, cardiac GRK2 upregulation in aging females is recapitulated by ovariectomy and can
be partially reversed by estrogen supplementation, while this does not occur in the skeletal muscle.
Our data indicate an unforeseen role for ovarian hormones in the regulation of GRK2 protein levels
in the cardiac muscle which correlates with the sex-dependent dynamics of CVD risk, and might
have interesting therapeutic applications, particularly for post-menopausal women.
Keywords: sexual dimorphism; cardiovascular disease; G protein-coupled receptor kinase 2; estro-
gens; mitochondria
1. Introduction
Cardiovascular disease (CVD) constitutes a global burden and stands as the leading
cause of morbidity and mortality worldwide [1,2]. Specifically, among women, it is the
premier cause of death in the United States [3]. Human studies and experiments performed
in animal models have revealed the occurrence of sex-biased sensitivity to the devel-
opment of CVD. Incidences of cardiovascular pathologies are lower in pre-menopausal
women compared to age-matched men. However, this apparent protection is lost with age,
particularly after menopause [4–7]. The systemic decline in estrogen levels after menopause,
such as 17 β-estradiol (E2) which is the major estrogen form, has been related to an increased
risk of CVD development with age in women, as supported by hormone replacement data
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from animal models [8–11] and early post-menopausal patients [12–15]. Among the mech-
anisms implicated in age-dependent sensitivity to CVD, the mitochondrial dynamics stand
out as a key modulator of cardiac output [16–18]. In particular, increased mitochondrial
fusion correlates with better mitochondrial functionality and cardiac health in young fe-
males [10,19] and, conversely, a lower fusion ability is associated with decreased cardiac
functionality [20,21].
G protein-coupled receptor kinase 2 (GRK2) plays an essential role in regulating
cardiovascular physiopathology by controlling cardiac contractility and inotropy, while also
modulating the mitochondrial dynamics and metabolism of the heart, given its unique
ability to impinge on both the G protein-coupled receptor (GPCR) signaling cascades
and the modulating non-canonical pathways [22,23]. Importantly, dysregulation of the
GRK2 levels is linked with diseased states in different cardio-metabolic conditions [24,25].
For instance, increased levels of GRK2 mRNA and protein activity have been reported in
the heart in experimental models of CVD [23,26]. The genetic deletion or pharmacologic
inhibition of GRK2 confers protection against heart failure, cardio-metabolic dysregulation,
and vascular dysfunction [22,27–31]. The mRNA levels of cardiac GRK2 appear to run
in parallel with protein quantity in the cardiac tissue and peripheral blood cells of both
CVD patients and murine models of disease [26,32]. GRK2 protein levels are tightly
controlled by proteasomal [26,33] or autophagic degradation [34] in different tissues and in
experimental settings. Recently, GRK2 has been shown in murine models to be altered in
a sexually dimorphic fashion in the liver, white adipose tissue, and skeletal muscle [35].
Nonetheless, the detailed mechanisms implicated in the modulation of GRK2 protein levels
in the heart remain to be characterized, especially in females.
We herein describe unforeseen sex- and age-dependent patterns of GRK2 modulation
in the murine heart which parallel the differential sensitivity described in the develop-
ment of CVD. Age-dependent GRK2 protein upregulation in females can be recapitulated
by the loss of ovarian hormones and are partly reverted by estrogen supplementation,
mediators that may lay at the basis of the sexual dimorphism observed in cardiac GRK2
dynamics.
2. Materials and Methods
2.1. Animal Protocols
Experiments were performed using young (~4 months old) and aged (~15 months
old) male and female C57 BL/6 J mice and Wistar rats. Animals were bred at a room
temperature of 22 ± 2 ◦C on a 12:12 light–dark cycle (lights on at 08:00 a.m.) with a relative
humidity of 50 ± 10% and under pathogen-free conditions in the animal facility of the
Centro de Biologia Molecular Severo Ochoa with free access to food and water. Mice and
rats were euthanized under fed conditions by cervical dislocation and cardiac and skeletal
muscle were dissected. All animal experimentation procedures conformed to the European
Guidelines for the Care and Use of Laboratory Animals (Directive 86/609) and were
approved by the Ethical Committees for Animal Experimentation of the Universidad
Autónoma de Madrid (PROEX 48/15).
2.2. Ovariectomy Model
Ovariectomy experiments were performed in female rats at Universitat de les Illes
Balears as previously described [10]. Briefly, control female Wistar rats and ovariec-
tomized rats were purchased from Charles River (Barcelona, Spain), where ovariectomies
(OVX group) and sham surgeries (control group) were performed at 5 weeks of age.
At ten weeks of age, OVX rats were divided into two experimental groups regarding their
treatment with estrogens: the OVX group was treated with 17 β-estradiol (OVX + E2),
administered by subcutaneous injection of 10 mg/kg of E2 every 48 h for 4 weeks previ-
ous to sacrifice (at 14 weeks of age); and the sham group (OVX) was treated with corn
oil (vehicle).
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2.3. Western Blotting
Mice or rats were euthanized by cervical dislocation or decapitation, respectively,
and the hearts and skeletal muscles (soleus and gastrocnemius) were surgically removed,
washed, dried, and frozen immediately in liquid nitrogen. Approximately 3 mm3 of the
heart and 14 of the dissected skeletal muscle (soleus and gastrocnemius) were homogenized
in hypotonic buffer with a Triton X-100 (150 µL and 400 µL of lysis buffer were used for
the heart and muscle, respectively) using metal beads in a Tissue Lyser with two 2 min
pulses of 1/30 s speed (Qiagen, Hilden, Germany) as previously described [30]. A total
protein quantity of 50 µg was resolved per lane by an SDS-PAGE and transferred to a
nitrocellulose membrane.
Blots were probed with specific antibodies against GRK2 (sc-562, Santa Cruz, Dallas,
TX, USA), OPA-1 (optic atrophy 1, #612606, BD Transduction Laboratories, Franklin Lakes,
NJ, USA), nucleolin (sc-13057, Santa Cruz, Dallas, TX, USA), p62 (GP62-C, Progen, London,
United Kingdom), LC3 (NB100-2220, Novus, Centennial, CO, USA), Mdm2 (AF1244, R&D
Systems, MN, USA), mono/poly-Ubiquitin (clone FK2, PW8810, Affinity Research Products
Limited San Francisco, CA, USA), β-Actin (127 M4866 V, Sigma, Santa Fe, NM, USA),
β-Tubulin (T4026, Sigma, Santa Fe, NeNM, USA), and GAPDH (Glyceraldehyde-3-Phosphate
Dehydrogenase, sc-32233, Santa Cruz, Dallas, TX, USA). Immunoreactive bands were visu-
alized using enhanced chemiluminescence (ECL; Amersham Biosciences, Buckinghamshire,
UK) or the Odyssey Infrared Imaging System (Li-Cor Biosciences, Lincoln, NE, USA).
Films were scanned with a GS-700 Imaging Densitometer and analyzed with Quantity One
Software (Bio-Rad, Hercules, CA, USA), or an Odyssey Classic reader and the Odyssey
software package 3.0 (Li-Cor Biosciences). Full membrane images of the gels can be found
in Supplementary Materials.
2.4. RT-qPCR from Rat and Mouse Tissues
In the rat samples, the total RNA from cardiac and skeletal muscle was obtained from
50 mg and 100 mg of tissue, respectively, using 1 mL Tripure® isolation reagent (Roche Di-
agnostics, Basel, Switzerland) following the manufacturer’s instructions, and quantified
using a Nanodrop system (BioTek, Winooski, VT, USA). One µg of total RNA was reverse
transcribed to cDNA using an M-MLV commercial kit (Invitrogen, Carlsbad, CA, USA).
The reaction was set up as follows: 25 ◦C (10 min), 37 ◦C (50 min), 70 ◦C (15 min) and 4 ◦C
in a Gene Amp 9700 thermal cycler (Applied Biosystems, Foster City, CA, USA), cDNA so-
lution was diluted 1/10 and stored at −20 ◦C until was analyzed. Real-time PCR was
performed using a LightCycler® 480 System II (Roche Diagnostics, Basel, Switzerland).
Each reaction contained 5 µL of LightCycler® 480 SYBR Green I master mix, sense and
antisense primers (0.374 µM each), and 2.5 µL of the cDNA dilution in a final volume of
10 µL. The amplification program consisted of a pre-incubation step for the denaturation
of template cDNA (95 ◦C, 2 min), followed by 40 cycles consisting of the denaturation
(95 ◦C, 5 min), annealing (primer-dependent temperature, 10 s), and extension steps
(72 ◦C, 12 s). The primer sequences and annealing temperatures used were: adrbk1_for:
5′-CATGCACAATCGCTTTGTAGTC-3′, adrbk1_rev: 5′-GGTCTGAGATTCTCACATGG- 3′
(58 ◦C); rpl32_for: 5′ -CCAGTCGGA CCGATATGTGAA- 3′, rpl32_rev: 5′ -TCTGGCCCTTGA
ATCTTCTCC- 3′ (60 ◦C); 18 s_for: 5′ -CGAACCTCCGACTTTCGTTCT- 3′, 18 s_rev: 5′-
GCGGTGAAATTCTTGGACCGG- 3′ (61 ◦C); gapdh_for: 5′ -ACTTTGGCATCG TGGAAGGG-
3′, gapdh_rev: 5′ -CCGTTCAGCTCTGGGATGAC- 3′ (60 ◦C).
In the mice, approximately 50 mg of frozen heart was homogenized using metal beads
in a Tissue Lyser (Qiagen, Hilden, Germany) and mRNA was extracted using RNeasy
Fibrous Tissue Mini Kits (Qiagen), following the instructions provided by the supplier.
RT-PCRs were performed by the Genomic Facility at the Centro de Biologia Molecu-
lar Severo Ochoa (abbreviated CBMSO, Madrid), using Light Cycler equipment (Roche,
Indianapolis, IN, USA). Gene expression quantifications were performed using self-designed
probes purchased from Sigma and labeled with Syber Green as follows: adrbk1_for: 5′-
CATGCACAATCGCTTTGTAGTC-3′, adrbk1_rev: 5′- GGTCCGAGATTCTCACATGG-3′;
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hprt1 for: 5′- TCCTCCTCAGACCGCTTTT-3′. hprt1 rev: 5′- CCTGGTTCATCATCGC-
TAATC -3′; rps29for: 5′- CTGAACATGTGCCGCCAGT-3′, rps29 rev: 5′- TCAAGGTCGCT-
TAGTCCAACTTAAT -3′; 18 s for: 5′-CTCAACACGGGAAACCTCAC-3′, 18 s rev: 5′-
CGCTCCACCAACTAAGAACG-3′. qPCRs and statistical analysis of the data were per-
formed using GenEx software. A geometric mean of three stably expressed and commonly
used reference genes (hprt, 18 s, and rps29) was used for data normalization.
2.5. Statistical Analysis
All data are expressed as mean values ± SEM and ‘n’ represents the sample size.
Statistical significance was analyzed using the unpaired Student’s t-test or one- or two-way
ANOVA followed by Bonferroni’s post-hoc test. Correlation between two data samples was
calculated using the Pearson correlation test. All data were analyzed using GraphPad Prism
software. Differences were considered statistically significant when p < 0.05. The threshold
cycle (Ct) values of the real-time PCR were analyzed using Genex software version 6 (Mul-
tiD Analyzes AB, Sweden), considering the efficiencies of each pair of primers, which were
calculated experimentally.
3. Results
3.1. GRK2 Levels Change with Age in a Sex-Dependent Manner in the Mouse Heart and Show an
Inverse Correlation with Mitochondrial Fusion Markers
As mentioned above, the CVD risk dynamics show sexual dimorphism with age.
Additionally, the role of GRK2 in regulating cardio-metabolic physiopathology in the
heart is well established [22,23]. However, the possibility that cardiac GRK2 protein levels
change with age in a sex-dependent fashion has not been addressed to date. To address
this question, we analyzed the amount of GRK2 protein in the heart of young (~4 months)
and aged (~15 months) male and female C57 Bl/6 J mice. We found that the GRK2
protein levels present with sexual dimorphism in the young animals and with a sex-
dependent differential modulation with age. Young females had a lower quantity of GRK2
as compared to age-matched males (Figure 1A). Moreover, GRK2 levels increased with
age solely in the female group, with a non-statistically significant tendency to decline
in males (Figure 1A). Since GRK2 has recently been shown to modulate mitochondrial
function in the heart [27,36], and mitochondrial fusion markers in High Fat Diet (HFD)-
fed male mice inversely relate to cardiac GRK2 levels [31], we analyzed the isoform
processing of optic atrophy (OPA1) as a readout of mitochondrial fusion capacity [37]
that has been shown to be sexually dimorphic in murine models [19]. We found a higher
ratio between the long and short OPA1 isoforms (L-OPA1/S-OPA1 ratio) in the young
females, compared to age-matched male animals (Figure 1A). This ratio did not change
with age in the male animals but we detected that it significantly decreased in females
with age (Figure 1B), coherent with the previously-described changes in mitochondrial
fusion detected in female mice [19]. Interestingly, we found a statistically robust inverse
correlation (p = 0.001) between normalized GRK2 levels and the L-OPA1/S-OPA1 ratio in
the cardiac tissue of our experimental group (Figure 1C). In any case, we would like to
point out that although the nucleolin normalization control does not change significantly
among conditions when related to the Ponceau staining as an accurate normalization
procedure [38], these types of normalizations should always be considered with caution,
since they are globally changing physiological conditions that may affect the levels of many
proteins and gene expression patterns.
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Figure 1. Age-associated changes in G protein-coupled receptor kinase 2 (GRK2) protein levels in the heart differ in male and
female mice and inversely correlate with the mitochondrial fusion marker optic atrophy (OPA1) isoform ratio. Cardiac tissue
lysates from C57BL/6 J mice of 4 months (young) or 15 months (aged) of age were analyzed by Western blot to quantify
GRK2 protein levels (A), OPA1 isoform ratio (B), and nucleolin used as a loading control. Equal protein amounts among
(Western blot) WB lanes was confirmed by Ponceau staining. Electrophoretic migration of molecular weight markers is
indicated. Correlation between GRK2 (A) and the L-OPA1/S-OPA1 ratio (B) was assessed by Pearson’s correlation (C).
Representative immunoblots and densitometric analysis correspond to n = 4–5 mice per condition. Results are represented as
means ± SEM. Statistical significance was analyzed by one-way ANOVA corrected by Bonferroni’s post-test and Pearson’s
correlation. * p < 0.05, ** p < 0.01, *** p < 0.001. GRK2 Rec, recombinant purified GRK2 protein from infected overexpressing
Sf9 cells.
3.2. Modulation of GRK2 Levels in the Heart Does Not Seem to Be Mediated by Transcriptional
Modulation or by Overall Changes in the Proteasomal or Autophagic Machinery
To further analyze how the GRK2 protein changes with sex or age, we measured the
GRK2 mRNA (adrbk1) levels by RT-qPCR in the hearts of these animals, since the tran-
scriptional modulation of the GRK2 dosage has been described in other contexts [22,31,39].
However, we could detect no significant sex- or age-dependent changes in adrbk1 expres-
sion (Figure 2A), which indicates that a post-transcriptional regulation must have taken
place. Since GRK2 levels have been shown to be regulated by proteasomal-dependent
degradation in cardiac tissue [33] and by autophagy in the liver [34], we tested the status
of general proteasomal or autophagic activity markers. As shown in Figure 2B, the levels
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of the ubiquitin ligase Mdm2, a key regulator of the proteasomal pathway known to be
implicated in the degradation of GRK2 [40], and the levels of mono/poly-ubiquitinated
proteins as a readout of global proteasomal activity, showed no statistically significant
differences that could serve explain the observed changes in the GRK2. The levels of
established autophagy markers such as LC3 processing or p62 accumulation (Figure 2C)
displayed neither global differences in autophagy in young females vs. young males nor
an autophagy blockage in aged vs. young females that could underlie age-dependent
GRK2 upregulation in the hearts of aging females, although this type of analysis does not
rule out that more specific variations may target defined proteins for degradation using
these systems.
Figure 2. Sex-related changes in cardiac GRK2 protein levels with age are not detected at the mRNA
level and overall proteasomal degradation or autophagy do not seem to be globally altered with age
or sex in mouse cardiac tissue. Male and female C57BL/6 J young and aged mice were euthanized and
the cardiac tissue was surgically removed and processed for RNA extraction. qPCR of GRK2 mRNA
levels (Adrbk1 normalized by a geometrical mean of HPRT1, 18 S, and RPS29) (A). General markers of
proteasomes (Mdm2 and mono/poly-Ubiquitin) (B), autophagy machinery (LC3 II and p62), and (C)
GAPDH as a loading control were quantified by Western blot. Fold change referred to young male
mice data. Results are represented as means ± SEM. Statistical significance was analyzed using
one-way ANOVA followed by Bonferroni’s post-hoc test.
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Estrogen levels modulate the GRK2 protein levels in the female heart and skeletal
muscle. Sexual hormones are depleted more abruptly with age in female animals than
in males, and therefore we reasoned that this differential factor might contribute to the
sexual dimorphism observed in cardiac GRK2 dynamics. We thus analyzed the impact of
ovariectomy and estrogen supplementation on cardiac GRK2 dosage in a murine model of
female Wistar rats. We observed that the lack of ovarian function promoted an increase
in cardiac GRK2 protein levels that could be partially reverted upon 17 β-estradiol (E2)
supplementation (Figure 3A). Coherent with the changes reported in adrbk1 mRNA in
aging females (Figure 2A), the upregulation of GRK2 protein in the heart upon the loss of
ovarian hormones did not appear to have been caused by hormone-triggered changes in the
transcription of the adrbk1 mRNA, since its levels did not change significantly upon ovariec-
tomy (Figure 3B). Additionally, the downregulation of GRK2 protein caused by E2 was not
due to transcriptional modulation since E2 does not have any effect on adrbk1 mRNA levels
(Figure 3B). Altogether, these results indicate that ovariectomy causes an increase in the
cardiac GRK2 protein that can be partially reversed by estrogen supplementation and that
does not seem to be caused by classical transcriptional modulation.
Figure 3. Cardiac GRK2 protein levels are modulated by sexual hormones in rats. Cardiac lysates
from female ovariectomized (OVX) animals and OVX rats, supplemented with 17β-estradiol
(OVX + E2), were subjected to WB with antibodies against GRK2 and GAPDH, n = 5–6 (A) or to
mRNA extraction and qPCR to assess adrbk1 levels (normalized to rpl32 and 18 s) n = 5–10 (B).
Representative immunoblots and densitometric analysis are shown, results are represented as
means ± SEM, statistical analyses were performed using one-way ANOVA followed by Bonfer-
roni’s post-hoc test (A,B) * p < 0.05.
Notably, the modulatory effect of ovarian hormones and particularly of estrogens on
GRK2 levels in cardiac muscle seemed to be specific to this tissue. In the skeletal muscle
of female mice, GRK2 levels decreased with age (Figure 4A), thus showing an opposite
regulation to that observed in the cardiac tissue. Contrary to what occurs in the heart, in rat
soleus and gastrocnemius muscles, we did not detect statistically significant changes in the
GRK2 protein levels after ovariectomy or E2 supplementation, although a tendency might
be observed (Figure 4B). In the skeletal muscle, ovariectomy significantly decreased adrbk1
mRNA expression, while E2 upregulated it (Figure 4C) although these changes were not
translated into changes in protein levels. These results suggest that different mechanisms
might be implicated in GRK2 modulation by estrogens in the cardiac and skeletal muscles.
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Figure 4. Modulation of GRK2 protein levels in females upon aging or ovariectomy in skeletal muscles
is opposite to that of the cardiac muscle. Young and aged female mice were euthanized, and the
soleus and gastrocnemius were surgically removed and processed for Western Blot and probed with
antibodies against GRK2 and β-actin. (A). Effects of ovariectomy and estradiol (E2) replacement
in the gastrocnemius muscle of rats probed with antibodies against GRK2 and normalized by the
Ponceau staining [38], n = 5–6, (B) and in adrbk1 mRNA levels normalized by gapdh as detected by
qPCR, n = 5–6 (C). Representative immunoblots and densitometric analysis of 4–6 animals per group
are shown. Results are represented as means ± SEM, statistical analyses were performed using
one-way ANOVA followed by Bonferroni’s post-hoc test (B,C) or an unpaired t-test (A) * p < 0.05,
** p < 0.01. GRK2 Rec, recombinant purified GRK2 protein from infected overexpressing Sf9 cells.
4. Discussion
GRK2 is a key regulator of cardiovascular physiopathology [22,23], and changes
in the GRK2 levels in the heart have been reported in different pathological situations,
including heart failure, hypertension, and lipid overload. Conversely, the expression of
GRKs is thought to be unaffected by age (reviewed in [41]). However, few studies on this
topic have been performed on females. In this work, we determined that aging induces an
increase in GRK2 levels in the heart only in female mice, and that cardiac GRK2 protein
levels are sensitive to ovarian hormones. Interestingly, this increase in GRK2 levels may
participate in the loss of protection against CVD found in females after menopause.
GRK2 protein levels in the heart parallel the differential sex- and age-dependent
sensitivity to the development of CVD. GRK2 levels are lower in young female mice,
as compared to age-matched males, and they increase significantly with age solely in
females, thus correlating with the loss of protection reported after menopause in both
human and animal models of CVD [4,5]. Moreover, the lower GRK2 dosage observed
in the young female heart inversely correlates with an increase in mitochondrial fusion
markers such as the L-OPA1/S-OPA1 ratio, which strengthens the relationship between
GRK2, the modulation of mitochondrial dynamics, and mitochondrial function [27,31,36,39].
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Thus, a characterization of the mechanisms underlying the sexual dimorphism observed
in age-induced regulation of cardiac GRK2 stands as a relevant question that may have
consequences in preserving cardiovascular health, in particular in postmenopausal females.
We show here that ovarian hormones and, in particular, estrogens have a clear impact on
GRK2 protein levels.
Estrogen levels decline after menopause and constitute the main contributor to the
increased CVD risk observed in females with age [12,15,42]. The observed benefits con-
ferred by estrogen supplementation support the use these strategies as feasible therapies
in both animal models [8,9,11] and early post-menopausal patients [12–15,43]. Both the
classical estrogen receptors (ERα and ERβ) and the plasma membrane GPR30 or the GPER
receptor (a member of the GPCR superfamily) have been reported to be implicated in
the protection of the heart by regulating gene expression through their nuclear actions
as well as by modulating the cardiomyocyte signaling pathways (reviewed in [12,43,44]).
In our model, cardiac GRK2 levels increased in rats upon ovariectomy, whereas estrogen
supplementation partially reversed this increase. These results demonstrate that ovarian
hormones, and particularly estrogens, are able to modulate GRK2 dosage in the heart.
Interestingly, we found a different modulation of GRK2 by ovariectomy and estrogen
supplementation in the skeletal muscle. We observed an opposite modulation of GRK2
between the skeletal and cardiac muscles in females with age, with a downregulation
taking place in the former and an upregulation being observed in the latter. It is thus
tempting to suggest that this differential modulation of GRK2 might have been caused by
the occurrence of the different tissue-specific regulatory mechanisms triggered by ovarian
hormones/estrogens which would be dependent on the muscle type. These modulations
could potentially occur by way of differential activation of the classical nuclear receptors
and/or the cytoplasmic actions of GPER that might mediate both the genomic and non-
genomic actions and ultimately impinge upon GRK2 modulation [45,46]. Estrogens have
been previously described as upregulating GRK2 levels in the brain [47] and breast cancer
cells [48], results that are in line with our data concerning the skeletal, but not in the cardiac,
muscles. Together, these observations may indicate that the regulation of GRK2 by ovarian
hormones and estrogens is controlled in the heart by tissue-specific mechanisms that are
not common to other organs or cell types. Particularly in the heart, these mechanisms
appeared to implicate post-transcriptional modulation without involving global changes in
autophagy or proteasome activity, at least as observed using the general markers of these
processes. However, we cannot discard the possibility that estrogens might be activating
or inhibiting these or other cellular processes in a more local or target-specific manner,
since estrogens have been determined to finely tune the activation of the autophagic and
proteasomal machinery in other tissue and cell types through their modulatory effects on
different pathways [49,50].
Previous evidence supports the notion that increasing GRK2 dosage or activity could
be detrimental for cardiovascular health due to its role as a negative regulator of the
GPCR and non-GPCR-mediated cascades and of insulin responses (see [22] for a review).
Likewise, interfering with GRK2 by decreasing its levels or inhibiting its kinase activity
can be protective [23,26,29,51,52]. Interestingly, GRK2 has also been reported to modulate
not only mitochondrial functionality [27,36,53], but also mitochondrial biogenesis and
dynamics [31,39]. Estrogen actions, specifically through GPER, can regulate mitochondrial
dynamics by promoting mitochondrial fusion [10,54,55] which correlates with better mi-
tochondrial functionality and cardiac health in young females [10,19], and which directly
contributes to sex- and age-dependent differences in cardiac health and metabolism [56–58].
In fact, mitochondrial dynamics are emerging as a core player in cardiovascular home-
ostasis, with their impairment being linked to myocardial damage and cardiac disease
progression [16,59,60]. Specifically, increased mitochondrial fusion has been shown to
benefit mitochondrial functionality by favoring optimal metabolite utilization in oxida-
tive phosphorylation and reactive oxygen species handling, which directly affects cardiac
metabolism and health [17,37,61,62]. Given the inverse correlation observed between GRK2
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and mitochondrial fusion markers such as OPA1 processing, it is tempting to suggest that
the GRK2-mediated modulation of this process could contribute to the increased mitochon-
drial functionality reported in young male vs. female mice [19] that is later lost in females
upon estrogen decline [10,63].
Our data suggest that the lower GRK2 dosage found in young female mice, as well
as its upregulation with age, could contribute to the age-biased sensitivity to the devel-
opment of CVD observed in women and female models [4,5,7,64]. We show here that
the estrogen decline that occurs upon menopause could contribute to the increase in
GRK2 observed in aging females, as suggested by the results in our ovariectomy model,
although the possible contribution of other ovarian hormones cannot be discarded. In fact,
it is tempting to speculate that decreased estrogen action and upregulated GRK2 levels
could potentially reinforce each other by establishing a vicious circle. Upregulated GRK2
(with age or as a consequence of comorbidities as obesity [31]) could desensitize the
GPER estrogen receptor as has already been suggested [65], through its canonical ac-
tions on GPCRs. In this potential scenario, estrogen signaling would in turn be impaired,
becoming inefficient at keeping GRK2 levels at bay in the heart. As a consequence, the GRK2
levels would remain upregulated, thus fostering its known maladaptive impact on cardiac
function and metabolism [22,23]. Also, the GPER-mediated estrogen protective actions
would be further decreased, which could worsen cardiac health, as observed in post-
menopausal females (see Figure 5). Given the global burden of CVD, specifically among
women, a better understanding of the regulatory loops that could take place between
GRK2 and estrogens could potentially help improve the treatment of post-menopausal
patients. Thus, this study may establish a proof-of-concept that selective therapies based
on GRK2 inhibitors, ideally combined with other therapeutic strategies, might be helpful
in the prevention and treatment of CVD, particularly in female patients.
Figure 5. Schematic representation of GRK2 modulation by estrogens in the heart and its parallels
with cardiovascular risk. In young female animals, high estrogen levels contribute to maintaining
a lower GRK2 dosage whereas, in age-matched males or aged females with lower estrogen levels,
higher GRK2 protein levels are detected. Elevated GRK2 levels would decrease GPCR-mediated
signaling, and potential estrogen-mediated effects, negatively impinging on mitochondrial fusion
markers such as OPA-1 processing which inversely correlate with GRK2 dosage. Thus, the GRK2-
mediated modulation of mitochondrial dynamics might potentially contribute to sex- and age-
dependent differences in mitochondrial functionality and cardiac health.
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